Richard G Stock, MD Email Richard Stock
- PROFESSOR | Radiation Oncology
- Radiation Oncology
- Hospital Affiliations
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- Radiation Oncology Associates 212-241-7503212-241-7503
Dr. Richard Stock has dedicated his career to delivering the highest quality care to patients using the most advanced technology available, including intensity modulated radiation therapy (IMRT), Novalis shaped beam radiosurgery, real-time ultrasound guided prostate seed implants and Mammosite, all of which allows for meticulously targeting the tumor while achieving maximal sparing of normal tissues.
Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society, where he is member at large, and as guest editor of a special Brachytherapy issue of Techniques in Urology. He has lectured and presented at dozens of meetings and symposiums across the country and internationally, including New York, San Francisco, Chicago, Philadelphia, Boston, Spain, Holland, France and Japan.
Dr. Stock completed his internship at Beth Israel Medical Center and his specialty training at Memorial Sloan-Kettering Cancer Center. He is listed in America's Top Doctors.
In the News
Dr. Stock discusses prostate cancer in The Daily News feature The Daily Check Up.
View the PDF.
Read the commentary by Richard G. Stock, MD, Simon J. Hall, MD, William K.Oh, MD, and David B. Samadi, MD, "Fighting Round Two: Recurrent Prostate Cancer" that appeared in the New York Times on June 8, 2010. View the PDF.
MD, Mount Sinai School of Medicine
Residency, Internal Medicine
Beth Israel Medical Center
Residency, Radiation Oncology
Dr. Stock's specific focus is prostate cancer and prostate brachytherapy. He established a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies. This has enabled him to obtain important medical information on the growing field of low dose rate brachytherapy and prostate cancer. Dr. Stock's efforts over the past 16 years, which includes 145 peer reviewed and invited papers, and book chapters, have contributed much to our understanding of prostate brachytherapy. He has helped set standards for dosing issues and implant quality. In addition, he has collaborated with other brachytherapy centers to publish multi-institutional series which have further enhanced our understanding of this treatment modality. Working in collaboration with other researchers, Dr. Stock has studied the relationship between genetic mutations and radiation side effects in patients undergoing radiation for prostate cancer. He is a co-investigator on a Department of Defense, American Cancer Society, and NIH RO1 grants to study this new and exciting area of research. In a recent publication in the International Journal of Radiation Oncology Biology Physics, Dr. Stock ranked among the top 4% of academic radiation oncologists in terms of the h-factor, a surrogate score for research productivity.
Stone NN, Stock RG, Cesaretti JA, Rosenstein B. Do high radiation doses in locally advanced prostate cancer patients treated with (103)Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? . Brachytherapy 2009 Oct 29;.
Stone NN, Stock RG, Cesaretti JA, Unger P. Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. Int J Radiat Oncol Biol Phys 2009 Jul 23;.
Potters L, Roach M 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. Postoperative Nomogram Predicting the 9-Year Probability of Prostate Cancer Recurrence After Permanent Prostate Brachytherapy Using Radiation Dose as a Prognostic Variable. Int J Radiat Oncol Biol Phys 2009 Jun 17;.
Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009 Aug 1; 115(5).
Stock RG, Cesaretti JA, Hall SJ, Stone NN. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009 Jun 2;.
Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009 Sep 1; 75(1): 16-22.
Stock RG, Klein TJ, Cesaretti JA, Stone NN. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009 Jul 1; 74(3): 753-758.
Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009 Jan; 67(1): 159-161.
Stock RG. Counterpoint: High-risk prostate cancer: the case for combination brachytherapy and external beam irradiation. Brachytherapy 2008 Oct-Dec; 7(4): 280-282.
Solan AN, Cesaretti JA, Stone NN, Stock RG. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009 Apr 1; 73(5): 1468-1474.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Stock did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.